Table 5.
Associations between the presence of CHD and expression of senescence-related endothelial and cardiomyocyte transcripts in peripheral blood
| Transcript | β coefficient | S.E.M. | 95% CI | P-value |
|---|---|---|---|---|
| Prevalent CHD at the time of assessment (125 cases compared with 125 controls) | ||||
| CTNNB1 | −0.07 | 0.26 | −0.59 to 0.44 | 0.786 |
| EDNRB | 0.26 | 0.16 | −0.04 to 0.56 | 0.092 |
| FN1(EIIIA) | −0.65 | 0.31 | −1.27 to −0.03 | 0.039 |
| FN1(EIIIB) | −0.16 | 0.29 | −0.72 to 0.40 | 0.580 |
| ICAM1 | −0.52 | 0.33 | −1.17 to 0.14 | 0.125 |
| IDV(1) | −0.09 | 0.20 | −0.48 to 0.30 | 0.655 |
| IDV(2) | −0.16 | 0.15 | −0.45 to 0.14 | 0.312 |
| ATP2A2(A) | −0.16 | 0.26 | −0.64 to 0.38 | 0.616 |
| ATP2A2(B) | −0.06 | 0.25 | −0.55 to 0.43 | 0.810 |
| VCAM1 | 0.09 | 0.10 | −0.12 to 0.29 | 0.394 |
| VEGFA121 | −0.05 | 0.23 | −0.50 to 0.40 | 0.832 |
| VEGFA165b | 0.98 | 0.44 | 0.13 to 1.83 | 0.024 |
| Incident CHD: Controls (n=134), Cases: category 1 (n=45), category 2 (n=80), category 3 (n=9) | ||||
| CTNNB1 | −0.08 | 0.24 | −0.55 to 0.40 | 0.758 |
| EDNRB | 0.25 | 0.15 | −0.04 to 0.54 | 0.090 |
| FN1(EIIIA) | −0.55 | 0.28 | −1.10 to −0.01 | 0.049 |
| FN1(EIIIB) | −0.21 | 0.28 | −0.76 to 0.35 | 0.465 |
| ICAM1 | −0.63 | 0.32 | −1.25 to −0.01 | 0.046 |
| IDV(1) | −0.06 | 0.19 | −0.44 to 0.32 | 0.770 |
| IDV(2) | −0.12 | 0.14 | −0.39 to 0.15 | 0.392 |
| ATP2A2(A) | −0.12 | 0.26 | −0.62 to 0.39 | 0.647 |
| ATP2A2(B) | −0.08 | 0.25 | −0.57 to 0.41 | 0.743 |
| VCAM1 | 0.15 | 0.10 | −0.04 to 0.34 | 0.131 |
| VEGFA121 | 0.03 | 0.23 | −0.41 to 0.41 | 0.892 |
| VEGFA165b | 0.91 | 0.41 | 0.11 to 1.70 | 0.025 |
| Incident CHD (men only): Controls (n=65), Cases: category 1 (n=21), category 2 (n=41), category 3 (n=3) | ||||
| CTNNB1 | −1.05 | 0.54 | −2.12 to 0.01 | 0.052 |
| EDNRB | 0.35 | 0.27 | −0.18 to 0.87 | 0.200 |
| FN1(EIIIA) | −3.91 | 5.20 | −14.11 to 6.28 | 0.452 |
| FN1(EIIIB) | 1.83 | 1.47 | −4.72 to 1.05 | 0.213 |
| ICAM1 | −1.07 | 0.49 | −2.03 to −0.12 | 0.028 |
| IDV(1) | −0.03 | 0.29 | −0.59 to 0.54 | 0.927 |
| IDV(2) | −0.44 | 0.23 | −0.90 to 0.02 | 0.062 |
| ATP2A2(A) | −0.18 | 0.39 | −0.94 to 0.58 | 0.648 |
| ATP2A2(B) | −0.12 | 0.40 | −0.90 to 0.65 | 0.757 |
| VCAM1 | 0.31 | 0.17 | −0.04 to 0.65 | 0.080 |
| VEGFA121 | −0.08 | 0.35 | −0.77 to 0.62 | 0.827 |
| VEGFA165b | 1.97 | 0.75 | 0.50 to 3.44 | 0.01 |
| Incident CHD (women only): Controls (n=69), Cases: category 1 (n=24), category 2 (n=39), category 3 (n=6) | ||||
| CTNNB1 | 0.53 | 0.36 | −0.18 to 1.24 | 0.142 |
| EDNRB | 0.23 | 0.24 | −0.23 to 0.70 | 0.325 |
| FN1(EIIIA) | −1.03 | 0.47 | −1.96 to −0.10 | 0.030 |
| FN1(EIIIB) | 0.20 | 0.37 | −0.51 to 0.92 | 0.578 |
| ICAM1 | −0.30 | 0.48 | −1.25 to 0.65 | 0.534 |
| IDV(1) | −0.12 | 0.30 | −0.71 to 0.48 | 0.701 |
| IDV(2) | 0.07 | 0.20 | −0.31 to 0.45 | 0.726 |
| ATP2A2 (A) | −0.17 | 0.38 | −0.92 to 0.57 | 0.648 |
| ATP2A2 (B) | −0.12 | 0.33 | −0.77 to 0.53 | 0.724 |
| VCAM1 | 0.10 | 0.14 | −0.18 to 0.38 | 0.489 |
| VEGFA121 | 0.09 | 0.31 | −0.53 to 0.70 | 0.777 |
| VEGFA165b | 0.19 | 0.55 | −0.89 to 1.26 | 0.735 |
Associations between transcript expression and CHD assessed by adjusted paired logistic regression analysis are given above. CHD is defined as the presence of angina or myocardial infarction. Cases are divided into category 1 (individuals with CHD diagnosed more than 3 years prior to the time of sampling), category 2 (individuals with CHD diagnosed less than 3 years prior to the time of sampling) and category 3 (individuals who did not have CHD at the time of sampling but who subsequently developed CHD more than 3 years after the time of sampling). Significant associations are given in bold italic type. Abbreviations: 95% CI, 95% confidence interval.